These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 28805086)

  • 1. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
    Scarisbrick JJ
    Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin in CD30
    Enos TH; Feigenbaum LS; Wickless HW
    Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab Beats Standard Therapies for CTCL.
    Cancer Discov; 2017 Mar; 7(3):OF3. PubMed ID: 28119332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
    Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
    J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.
    Welborn M; Duvic M
    Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
    Prince HM; Kim YH; Horwitz SM; Dummer R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Trotman J; Taylor K; Dalle S; Weichenthal M; Walewski J; Fisher D; Dréno B; Stadler R; Feldman T; Kuzel TM; Wang Y; Palanca-Wessels MC; Zagadailov E; Trepicchio WL; Zhang W; Lin HM; Liu Y; Huebner D; Little M; Whittaker S; Duvic M;
    Lancet; 2017 Aug; 390(10094):555-566. PubMed ID: 28600132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
    Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
    Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brentuximab vedotin in CD30
    Stranzenbach R; Dippel E; Schlaak M; Stadler R
    Br J Dermatol; 2017 Dec; 177(6):1503-1509. PubMed ID: 28703284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
    Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
    J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
    Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
    Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
    Elsea D; Savage KJ; Lilley C; Lisano J; Liu J; Yu KS
    Adv Ther; 2023 May; 40(5):2326-2338. PubMed ID: 36920744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of mycosis fungoide : focus on brentuximab vedotin].
    Lebas E; Collins P; Bonnet C; Libon F; Dezfoulian B; Nikkels AF
    Rev Med Liege; 2021 Apr; 76(4):224-231. PubMed ID: 33830684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States.
    Barta SK; Liu N; DerSarkissian M; Chang R; Ye M; Duh MS; Surinach A; Fanale M; Yu KS
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):e21-e32.e4. PubMed ID: 37919137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin in anaplastic large cell lymphoma.
    Skarbnik AP; Smith MR
    Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
    Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
    Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.
    Lewis DJ; Talpur R; Huen AO; Tetzlaff MT; Duvic M
    JAMA Dermatol; 2017 Dec; 153(12):1302-1306. PubMed ID: 28980004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
    Horwitz SM; Scarisbrick JJ; Dummer R; Whittaker S; Duvic M; Kim YH; Quaglino P; Zinzani PL; Bechter O; Eradat H; Pinter-Brown L; Akilov OE; Geskin L; Sanches JA; Ortiz-Romero PL; Weichenthal M; Fisher DC; Walewski J; Trotman J; Taylor K; Dalle S; Stadler R; Lisano J; Bunn V; Little M; Prince HM
    Blood Adv; 2021 Dec; 5(23):5098-5106. PubMed ID: 34507350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brentuximab vedotin.
    van de Donk NW; Dhimolea E
    MAbs; 2012; 4(4):458-65. PubMed ID: 22684302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
    Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
    Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.